PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	000 Form BOT/ID 4 /000
P734 PC00	ACTION as we	see Form PCT/ISA/220 ell as, where applicable, Item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/DK2004/000259	07/04/2004	11/04/2003
Applicant	,	
VP > FPMHNO PERSON OF		
KRAEFTENS BEKAEMPELSE		
This International Search Report has beer according to Article 18. A copy is being tra	n prepared by this International Searching Au Insmitted to the International Bureau.	thority and is transmitted to the applicant
This International Search Report consists	of a total of8 sheets.	
It is also accompanied by	a copy of each prior art document cited in this	s report.
Basis of the report		
 a. With regard to the language, the i language in which it was filed, unle 	nternational search was carried out on the ba ess otherwise indicated under this item.	asis of the international application in the
The international sthis Authority (Rule	search was carried out on the basis of a trans	slation of the international application furnished to
b. X With regard to any nucleo	tide and/or amino acid sequence disclosed	d in the International application, see Box No. I.
2. Certain claims were foun	d unsearchable (See Box II).	
3. Unity of invention is lack	ing (see Box III).	
4. With regard to the title,		
X the text is approved as sub	mitted by the applicant.	
the text has been establish	ed by this Authority to read as follows:	
·		
5. With regard to the abstract,		
X the text is approved as sub		
may, within one month from	ed, according to Hule 38.2(b), by this Authori I the date of mailing of this international seam	ty as it appears in Box No. IV. The applicant ch report, submit comments to this Authority.
6. With regards to the drawings,		
	blished with the abstract is Figure No.	·
as suggested by the		
	Authority, because the applicant failed to sug	
b. X none of the figures is to be	Authority, because this figure better characte published with the abstract	rizes the invention.
		

International application No.

PCT/DK2004/000259

x No	. 1	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
W	ith rega vention	ard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the daimed , the international search was carried out on the basis of:
a.	type	e of material
	х	a sequence listing
		table(s) related to the sequence listing
b.	form	nat of material
	Х	in written format
	Х	in computer readable form
c.	time	of filing/furnishing
	х	contained in the International application as filed
	X	filed together with the international application in computer readable form
		furnished subsequently to this Authority for the purpose of search
	OI.	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed furnished, the required statements that the information in the subsequent or additional copies is identical to that in the optication as filed or does not go beyond the application as filed, as appropriate, were furnished.
Ad	ditional	comments:
		\cdot
		·
		·

International Application No PCT/DK 2004/000259

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 CO7K14/47 A61k A61K39/00 C07K16/30 C12N5/06 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07KDocumentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, Sequence Search, WPI Data, EMBASE, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Category º Cliation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X SCHMOLLINGER JAN C ET AL: "Melanoma 27,52,53 inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 6, 18 March 2003 (2003-03-18), pages 3398-3403, XP002293965 ISSN: 0027-8424 page 3400, left-hand column, paragraph 2 page 3400, right-hand column, paragraph 2 γ page 3400, right-hand column, paragraph 2 1 - 54page 3401, right-hand column, paragraph page 3403, left-hand column, paragraph 2 page 3403, right-hand column, paragraph 1 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priorily date and not in conflict with the application but cited to understand the principle or theory underlying the 'A' document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed Invention filing date occument or paticular relevance, the claimed invertion cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu- O document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 17 September 2004 07/10/2004 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Aşswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni. Huber, A Fax: (+31-70) 340-3016

International Application No
PCT/DK2004/000259

Calegory* Citation of document, with indication, where appropriate, of the relevant passages PATENT ABSTRACTS OF JAPAN vol. 2003, no. 02, 5 February 2003 (2003–02–05) 8 JP 2002 284797 A (HOKKAIDO TECHNOLOGY LICENCE OFFICE CO LTD), 3 October 2002 (2002–10–03) abstract ANDERSEN M H ET AL: "Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 16, 15 August 2001 (2001–08–15), pages 5964–5968, XPO02283854 ISSN: 0008–5472 the whole document WO 00/03693 A (JENNER BIOTHERAPIES INC) 27 January 2000 (2000–01–27) page 4, line 27 - page 6, line 21; claims 1–11 WO 00/77201 A (ASTRAZENECA UK LTD; ASTRAZENECA AB (SE)) 21 December 2000 (2000–12–21) claims 1–22; sequences 3,11	C (Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/DK2004/000259			
vol. 2003, no. 02, 5 February 2003 (2003-02-05) & JP 2002 284797 A (HOKKAIDO TECHNOLOGY LICENCE OFFICE CO LTD), 3 October 2002 (2002-10-03) abstract ANDERSEN M H ET AL: "Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 16, 15 August 2001 (2001-08-15), pages 5964-5968, XP002283854 ISSN: 0008-5472 the whole document WO 00/03693 A (JENNER BIOTHERAPIES INC) 27 January 2000 (2000-01-27) page 4, line 27 - page 6, line 21; claims 1-11 WO 00/77201 A (ASTRAZENECA UK LTD; ASTRAZENECA AB (SE)) 21 December 2000 (2000-12-21) claims 1-22; sequences 3,11 ANDERSEN MADS HALD ET AL: "The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 2, February 2004 (2004-02), pages 392-399, XP002293966 ISSN: 0022-202X						
vol. 2003, no. 02, 5 February 2003 (2003-02-05) & JP 2002 284797 A (HOKKAIDO TECHNOLOGY LICENCE OFFICE CO LTD), 3 October 2002 (2002-10-03) abstract ANDERSEN M H ET AL: "Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 16, 15 August 2001 (2001-08-15), pages 5964-5968, XP002283854 ISSN: 0008-5472 the whole document WO 00/03693 A (JENNER BIOTHERAPIES INC) 27 January 2000 (2000-01-27) page 4, line 27 - page 6, line 21; claims 1-11 WO 00/77201 A (ASTRAZENECA UK LTD; ASTRAZENECA AB (SE)) 21 December 2000 (2000-12-21) claims 1-22; sequences 3,11 ANDERSEN MADS HALD ET AL: "The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 2, February 2004 (2004-02), pages 392-399, XP002293966 ISSN: 0022-202X						
cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 16, 15 August 2001 (2001-08-15), pages 5964-5968, XP002283854 ISSN: 0008-5472 the whole document WO 00/03693 A (JENNER BIOTHERAPIES INC) 27 January 2000 (2000-01-27) page 4, line 27 - page 6, line 21; claims 1-11 WO 00/77201 A (ASTRAZENECA UK LTD; ASTRAZENECA AB (SE)) 21 December 2000 (2000-12-21) claims 1-22; sequences 3,11 P,X ANDERSEN MADS HALD ET AL: "The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses:" JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 2, February 2004 (2004-02), pages 392-399, XP002293966 ISSN: 0022-202X	Y	vol. 2003, no. 02, 5 February 2003 (2003-02-05) & JP 2002 284797 A (HOKKAIDO TECHNOLOGY LICENCE OFFICE CO LTD), 3 October 2002 (2002-10-03)	1-54			
27 January 2000 (2000-01-27) page 4, line 27 - page 6, line 21; claims 1-11 WO 00/77201 A (ASTRAZENECA UK LTD; ASTRAZENECA AB (SE)) 21 December 2000 (2000-12-21) claims 1-22; sequences 3,11 ,X ANDERSEN MADS HALD ET AL: "The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 2, February 2004 (2004-02), pages 392-399, XP002293966 ISSN: 0022-202X		cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 16, 15 August 2001 (2001-08-15), pages 5964-5968, XP002283854 ISSN: 0008-5472	1-54			
ASTRAZENECA AB (SE)) 21 December 2000 (2000-12-21) claims 1-22; sequences 3,11 ,X ANDERSEN MADS HALD ET AL: "The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 2, February 2004 (2004-02), pages 392-399, XP002293966 ISSN: 0022-202X		27 January 2000 (2000-01-27) page 4, line 27 - page 6, line 21; claims	1-54			
inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 2, February 2004 (2004-02), pages 392-399, XP002293966 ISSN: 0022-202X	1	ASTRAZENECA AB (SE)) 21 December 2000 (2000-12-21)	1-13			
	P , X	inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 2, February 2004 (2004-02), pages 392-399, XP002293966 ISSN: 0022-202X	1-54			

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 41-46 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 14-18 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

International application No. PCT/DK2004/000259

INTERNATIONAL SEARCH REPORT

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Х	Claims Nos.: because they relate to subject matter not required to be searched by this Authority. namely: see FURTHER INFORMATION sheet PCT/ISA/210
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
·	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. X	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark o	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Information on patent family members

International Application No PCT/DK2004/000259

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
JP 2002284797	Α	03-10-2002	NONE		
WO 0003693	A	27-01-2000	AU WO	4990999 A 0003693 A1	07-02-2000 27-01-2000
WO 0077201	Α	21-12-2000	AU WO US	5544500 A 0077201 A1 2003087319 A1	02-01-2001 21-12-2000 08-05-2003